Is Johnson & Johnson a Buy for Summer 2021?
Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (NYSE: JNJ): Its stock has underperformed the index by more than 20 percentage points over the past 12 months.
That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today?
Image source: Getty Images.
Source Fool.com
